| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/24/2004 | US6696452 Glycogen synthase kinase-3 and aurora-2 a serine/threonine protein kinase inhibitors; antidiabetic and anticancer agents and alzheimer's disease treatments |
| 02/24/2004 | US6696440 Administering mitogen activated protein kinase(mek) inhibitors comprising secondary carbocyclic amines, as antiasthmatic agents |
| 02/24/2004 | US6696433 Use of sex steroids function modulators to treat wounds and fibrotic disorders |
| 02/24/2004 | US6696432 Combination of dehydroepiandrosterone and aromatase inhibitors and use of this combination to produce a medicament for treating relative and absolute androgen deficiency in men |
| 02/24/2004 | US6696428 Use of dopamine receptor antagonists in palliative tumor therapy |
| 02/24/2004 | US6696425 Stimulating tear secretion and mucin production in eyes of a subject by administering certain uridine, adenine, or cytidine triphosphates as well as other dinucleoside polyphosphate compounds |
| 02/24/2004 | US6696422 Parenterally administering product r, a peptide-nucleic acid preparation, in combination with one or more antiviral agents useful for treating aids or hiv infections including hiv protease inhibitors and nucleosides |
| 02/24/2004 | US6696412 Purification of daptomycin by binding to ion exchange resins in the presence of buffers and chaotropic agents, then eluting and recovering; peptide antibiotics |
| 02/24/2004 | US6696268 Production and use of antimicrobial agents |
| 02/24/2004 | US6696089 Nanogel networks including polyion polymer fragments and biological agent compositions thereof |
| 02/24/2004 | US6696088 Useful for decreasing the potential for abuse of the opioid agonist contained therein; for use in therapy of pain |
| 02/24/2004 | US6696084 Spray drying process and compositions of fenofibrate |
| 02/24/2004 | US6696083 Administering vitamin b1, thiamine, niacinamide, folic acid, riboflavin, pantothenic acid, vitamin b, pyridoxine, and/or vitamin b12 to human during sleep; oxidation resistance |
| 02/24/2004 | US6696072 Mixture of phentolamine mesylate, papaverine hydrochloride, and alprostadil in buffer containing l-arginine and glycine injected into penis |
| 02/24/2004 | US6696066 Opioid agonist/antagonist combinations |
| 02/24/2004 | US6696042 Inhalation aerosol comprising tiotropium salt and propellant gas; respiratory system disorders |
| 02/24/2004 | US6696038 Cationic lipopolymer as biocompatible gene delivery agent |
| 02/19/2004 | WO2004015140A1 Methods for the treatment of dementia based on apo e genotype |
| 02/19/2004 | WO2004015131A2 Hepatitis c virus assays |
| 02/19/2004 | WO2004015109A1 Human acid sensing ion channel 2b (hasic2b), process for producing the same, and its use |
| 02/19/2004 | WO2004015089A2 Polyionic organic acid formulations |
| 02/19/2004 | WO2004015072A2 Mrbs as modifiers of the rb pathway and methods of use |
| 02/19/2004 | WO2004014852A2 Iminothiazolidinones as inhibitors of hcv replication |
| 02/19/2004 | WO2004014851A2 Tyrosine kinase inhibitors |
| 02/19/2004 | WO2004014825A1 Cannabinoid receptor ligands |
| 02/19/2004 | WO2004014430A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | WO2004014426A1 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer |
| 02/19/2004 | WO2004014413A1 Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto |
| 02/19/2004 | WO2004014386A1 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies |
| 02/19/2004 | WO2004014380A1 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| 02/19/2004 | WO2004014373A1 Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases |
| 02/19/2004 | WO2004014367A2 Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease |
| 02/19/2004 | WO2004014355A1 A peritoneal dialysis solution comprising a pyruvate |
| 02/19/2004 | WO2004014352A2 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | WO2004014343A1 Storage stable tablets of fosinopril sodium |
| 02/19/2004 | WO2004014322A2 Immunomodulatory compositions, methods of making, and methods of use thereof |
| 02/19/2004 | WO2004014319A2 Screening strategy for anticancer drugs |
| 02/19/2004 | WO2004014313A2 Combination pharmaceutical agents as inhibitors of hcv replication |
| 02/19/2004 | WO2004014304A2 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | WO2004014301A2 PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE |
| 02/19/2004 | WO2004014293A2 Combination of anti-muscarinic agents and non-glucocorticoid steroids |
| 02/19/2004 | WO2004014222A2 Diagnosis and treatment of tuberous sclerosis |
| 02/19/2004 | WO2004006953A3 Vaccine against salmonid rickettsial septicaemia based on arthrobacter cells |
| 02/19/2004 | WO2004002463A3 Method of promoting smoking cessation |
| 02/19/2004 | WO2004000840A3 Quinuclidine derivatives and pharmaceutical compositions containing the same |
| 02/19/2004 | WO2003099223A3 Copper lowering treatment of inflammatory and fibrotic diseases |
| 02/19/2004 | WO2003097852A3 Assay for identifying inhibitors of fc gamma riii signaling |
| 02/19/2004 | WO2003092603A3 Composition and method for reducing post-prandial blood glucose |
| 02/19/2004 | WO2003075850A9 Methods for alzheimer's disease treatment and cognitive enhancement |
| 02/19/2004 | WO2003075790A3 Gas-plasma treatment of implants |
| 02/19/2004 | WO2003070188A3 Method of treating trx mediated diseases |
| 02/19/2004 | WO2003065988A3 A combination for treating cold and cough |
| 02/19/2004 | WO2003065987A3 Granzyme b inhibitors |
| 02/19/2004 | WO2003065046A3 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| 02/19/2004 | WO2003053474A3 Use of micro-organisms for a directed delivery of substances to specific parts of the gut |
| 02/19/2004 | WO2003053136A3 Triple transgenic mouse model of alzheimer's disease |
| 02/19/2004 | WO2003049593A3 Prevention of flap necrosis in plastic surgery |
| 02/19/2004 | WO2003048780A3 Uses of aldose-1-epimerase (mutarotase) for diagnosis and therapy of inflammatory diseases and sepsis |
| 02/19/2004 | WO2003048384A3 Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determing single nucleotide polymorphisms |
| 02/19/2004 | WO2003046564A3 Protein biopolymer markers predictive of alzheimers disease |
| 02/19/2004 | WO2003043639A3 PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER |
| 02/19/2004 | WO2003043615A3 Hypertonia treatment during the acute phase of a cerebrovascular accident |
| 02/19/2004 | WO2003043576A3 Flowable osteogenic and chondrogenic compositions |
| 02/19/2004 | WO2003037168A3 Methods and formulations for minimizing spasticity in blood vessel grafts |
| 02/19/2004 | WO2003034028A3 Methods for identifying and using modulators of estrogen related receptor gamma |
| 02/19/2004 | WO2003030947A3 Concentrated x-ray contrast media can act as universal antigens and can inhibit or prevent allergic reactions |
| 02/19/2004 | WO2003014731A3 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 02/19/2004 | WO2002090514A8 Epidermal growth factor receptorantisense oligonucleotides |
| 02/19/2004 | WO2002078736A3 Antiallergic pharmaceutical composition |
| 02/19/2004 | WO2002074290A3 Dermatological preparations containing a nsaid |
| 02/19/2004 | WO2002064160A3 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 02/19/2004 | WO2002048337A3 Secreted human proteins |
| 02/19/2004 | WO2002046477A3 Endogenous retroviruses up-regulated in prostate cancer |
| 02/19/2004 | WO2002042328A3 Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon |
| 02/19/2004 | WO2002032429A3 Use of inhibitors of progesterone receptor for treating cancer |
| 02/19/2004 | WO2002024214A3 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 02/19/2004 | WO2001020981A3 Anti-infective compositions for treating disordered tissue such as cold sores |
| 02/19/2004 | US20040034357 Controlled release implantable devices |
| 02/19/2004 | US20040034237 Materials and methods for the treatment of hypertension and angina |
| 02/19/2004 | US20040034229 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists |
| 02/19/2004 | US20040034221 Enzyme inhibitors for treating AIDS |
| 02/19/2004 | US20040034209 Using genetic vaccine to treat and prevent infection by lymphadenopathy associated virus; viricides |
| 02/19/2004 | US20040034206 Administering therapeutically effective amount of ribavirin, (S)-N-3-(3-(3-methoxy-4-oxazol-5-yl-phenyl)ureido)benzylcarbam ic acid tetrahydrofuran-3-yl-ester, and pegylated interferon-alpha-2b |
| 02/19/2004 | US20040034100 Treating neuronal injury and for life-extension |
| 02/19/2004 | US20040034098 Methods and compositions for preventing chronological aging in human skin |
| 02/19/2004 | US20040034093 Methods for enhancing motor performance and/or endurance |
| 02/19/2004 | US20040034087 Comprises phosphodiesterase inhibitor and beta-2-adrenoceptor agonist; for treatment of respiratory tract disorders |
| 02/19/2004 | US20040034085 For treatment of cartilage damage, inflammation, arthritis, and pain; treating diseases such as rheumatoid arthritis/osteoarthritis, heart failure, multiple sclerosis, atherosclerosis, and osteoporosis |
| 02/19/2004 | US20040034084 Side effect reduction; for treatment of AIDS, cancer and arthritis |
| 02/19/2004 | US20040034083 Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s) |
| 02/19/2004 | US20040034065 A mixture of valsartan, an insulin secretion enhancer or a insulin sensitizer, for treating hypertension, congestive heart failure, diabetes, type 2 diabetes, renal failure, premenstrual syndrome, coronary heart disease |
| 02/19/2004 | US20040034052 Antitumor agents |
| 02/19/2004 | US20040034030 A unit dosage form as adjuvant to biguanide (metformin) or sulfonylurea (glyburide) therapy for supporting mitochondrial metabolism containing carnitine, ascorbic acid, choline, taurine, foic acid and magnesium; side-effect reduction |
| 02/19/2004 | US20040034029 Composition and method for altering levels of or sensitivity to adenosine with a dehydroepiandrosterone |
| 02/19/2004 | US20040034026 The use of a vasculostatic compound and a second active ingredient which decreases the activity of the epidermal growth factor (EGF); synergistic, angiogenesis inhibitors; antiproliferative agents; tyrosine kinase enzyme inhibitors |
| 02/19/2004 | US20040034021 Intravenous rifalazil formulation and methods of use thereof |
| 02/19/2004 | US20040034020 A purine deriveative, useful for treatment of inflammatory conditions, immune disorders, tissue injury, infections, and cancer |
| 02/19/2004 | US20040034019 Piperazine and piperidine derivatives |
| 02/19/2004 | US20040034008 N-alkylpiperdino-4-yl-urea-pyrazole derivative for treating obesity, metabolic disorders, eating disorders and diabetes |
| 02/19/2004 | US20040034000 Methods of treating and/or suppressing insulin resistance |